Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

被引：0
|
作者：
Sekeres, Mikkael A.
Komrokji, Rami S. [2 ]
Lancet, Jeffrey E. [2 ]
Tiu, Ramon V. [1 ]
Advani, Anjali S.
Afable, Manual [1 ]
Englehaupt, Ricki [1 ]
Juersivich, Joyce [1 ]
Cuthbertson, David [3 ]
Paleveda, Jennifer [2 ]
Paquette, Ronald
Smith, April [1 ]
Strozniak, Lori [1 ]
List, Alan F. [4 ]
Maciejewski, Jaroslaw P. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Univ S Florida, Pediat Epidemiol Ctr, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：279 / 279
页数：1
相关论文
共 50 条
  • [1] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2008, 112 (11) : 88 - 89
  • [2] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Tiu, Ramon V.
    Komrokji, Rami
    Lancet, Jeffrey
    Advani, Anjali S.
    Afable, Manuel
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Tabarroki, Ali
    Visconte, Valeria
    Makishima, Hideki
    Jerez, Andres
    Paquette, Ronald
    List, Alan F.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2012, 120 (25) : 4945 - 4951
  • [3] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [4] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Ganetsky, Rebecca
    Latham, Deborah
    Paulic, Katarina
    Afable, Manuel
    Saba, Hussain I.
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
  • [5] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    [J]. BLOOD, 2013, 122 (21)
  • [6] Azacitidine Combination with Lenalidomide in Treating Higher-Risk Myelodysplastic Syndromes: A Single-Center, Phase 2 Trial
    Song, Dandan
    Ge, Zheng
    [J]. BLOOD, 2023, 142
  • [7] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [8] Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol
    Mittelman, Moshe
    Filanovsky, Kalman
    Rosenbaum, Hanna
    Raanani, Pia
    Braester, Andrei
    Goldschmidt, Neta
    Hellman, Ilana
    Kirgner, Ilya
    Perrii, Chava
    Oster, Howard S.
    [J]. BLOOD, 2013, 122 (21)
  • [9] Preliminary results from a phase I study of Revlimid® (Lenalidomide) in combination with Vidaza® (Azacitidine) in patients with advanced myelodysplastic syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan
    Cuthbertson, David
    Paquette, Ronald
    Loughran, Thomas
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2007, 110 (11) : 437A - 437A
  • [10] Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    O'Keefe, Christine
    List, Alan F.
    Paulic, Katarina
    Afable, Manuel, II
    Englehaupt, Ricki
    Maciejewski, Jaroslaw P.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 102 - 103
12345